Invention Grant
US07932256B2 (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
有权
（S）-4-（1-环丙基-2-甲氧基乙基）-6-（6-（二氟甲氧基）-2,5-二甲基吡啶-3-基氨基）-5-氧代-4,5-二氢吡嗪-2-甲腈： 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂
- Patent Title: (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
- Patent Title (中): （S）-4-（1-环丙基-2-甲氧基乙基）-6-（6-（二氟甲氧基）-2,5-二甲基吡啶-3-基氨基）-5-氧代-4,5-二氢吡嗪-2-甲腈： 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂
-
Application No.: US12429810Application Date: 2009-04-24
-
Publication No.: US07932256B2Publication Date: 2011-04-26
- Inventor: Richard A. Hartz , Vijay T. Ahuja , Vivekananda M. Vrudhula , Joanne J. Bronson
- Applicant: Richard A. Hartz , Vijay T. Ahuja , Vivekananda M. Vrudhula , Joanne J. Bronson
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent James Epperson
- Main IPC: A61K31/4965
- IPC: A61K31/4965
Abstract:
The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
Public/Granted literature
- US20100029684A1 Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity Public/Granted day:2010-02-04
Information query
